Navigation Links
QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
Date:1/9/2012

HILDEN and BERLIN, Germany, January 9, 2012 /PRNewswire/ --

  • Collaboration to create molecular test assessing a person's risk for latent TB progressing to active TB, enabling early treatment and disease outbreak prevention
  • QIAGEN strengthening its leading infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB
  • New assay will use whole blood transcription profiling - a new diagnostic technology developed at the Max Planck Institute's Department of Immunology
  • New molecular test to be run on the QIAsymphony modular automation platform

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt: Prime Standard: QIA) and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed.

Approximately one-third of the world's population is estimated to be infected with Mycobacterium tuberculosis, but do not have active tuberculosis. The identification and treatment of these individuals is critical to controlling this disease since approximately 5-10% of latent TB patients are at risk for developing active TB during their lifetime, particularly those with weakened immune systems.  

As a follow-up to those who test positive for latent TB, this new test will be designed to enable early treatment before reactivation of the TB disease, when it becomes contagious and causes life-threatening respiratory illnesses and other diseases.

This new mol
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
2. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
3. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
4. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
5. QIAGEN Acquires Exclusive Licence for Key PI3K gene
6. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
8. Plexus Awarded Development Contract With QIAGEN
9. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
10. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
11. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015  scPharmaceuticals, ... transformative pharmaceutical products for subcutaneous delivery, announced ... trial of its investigational proprietary drug product, ... edema associated with congestive heart failure. ... is developing a proprietary patch pump.  The ...
(Date:4/21/2015)... 2015 Progyny, Inc., the new combined ... that it has secured additional capital from investors including ... One and Merck Serono Ventures. The funding will enable ... best fertility outcomes by aligning science, technology, clinics and ... for families seeking fertility solutions and we are committed ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 YourEncore, ... the life sciences, consumer products and food sciences ... and the Alliance for Clinical Research Excellence and ... system for conducting clinical research, have partnered to ... , YourEncore brings to ACRES experts ...
(Date:4/20/2015)... , April 20, 2015 Orthobiologics ... healing bone injuries. The orthobiologics market is a rewarding ... its stakeholders. The global orthobiologics market report defines and ... revenue. The global orthobiologics market was valued at $5,712.4 ... million by 2019, at a CAGR of 6.7% from ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 3Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... technique long used by statisticians to analyze data is ... learning, Alzheimer,s and Parkinson,s diseases and stroke. Researchers ... Science Center at Houston (UTHealth) reported today in the ... fluorescence resonance energy transfer (FRET) techniques combined with wavelet ...
... / PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: ... intended to more closely align its corporate structure ... President Research, will assume responsibility for the entire ... Essentials, Research Specialties and Research Biotech.  This newly ...
... 2011 Chimerix, Inc., a pharmaceutical company developing orally ... awarded a contract by the Biomedical Advanced Research and ... broad spectrum antiviral drug candidate, CMX001, as a medical ... CMX001 is a potential dual-use therapeutic with ...
Cached Biology Technology:Researchers get a grip on nervous system's receptors 2Researchers get a grip on nervous system's receptors 3Sigma-Aldrich Announces Organizational Changes 2Sigma-Aldrich Announces Organizational Changes 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 2Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 3Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox 4
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... FLA research team led by Cary Pirone from the ... identified bilirubin in the popular Bird of Paradise plant. ... of the American Society for Horticultural Science,s journal ... this iconic tropical plant. Previously thought to ...
... from door-to-door interviews, Stanford University geographer Eric Lambin and ... rise to a broad range of land-use challenges ... Lyme disease in Belgium. For decades, orbiting satellites ... of the Earth, giving scientists an unprecedented view of ...
... development and successful initial tests on a substance that ... a fungus, brightening prospects for wider use of the ... that attack food crops. "Our finding is especially important ... control treatments like this will help to reduce dependence ...
Cached Biology News:First discovery of bilirubin in a flower announced 2Stanford land-use expert brings satellite data down to Earth 2Stanford land-use expert brings satellite data down to Earth 3Stanford land-use expert brings satellite data down to Earth 4
Request Info...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Biology Products: